News

Actions

Sixth blood pressure medication recalled over carcinogen concerns

Posted at 10:19 AM, Jan 02, 2019
and last updated 2019-01-02 13:39:34-05

EAST WINDSOR, N.J. – Another blood pressure medication has been recalled over concerns it could contain trace amounts of carcinogens. 

The medication is manufactured by Aurobino Pharma USA, Inc. The recall is voluntary.

It affects 80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP.

If you take the drug, contact your doctor.

You can check out all the latest drug recalls here.

Six blood pressure medications have been recalled since November.

All have been found to have trace amounts of N-nitrosodiethylamine (NDEA) and are manufactured by different companies.

The blood pressure medications still under recall according to the FDA: Aurobindo (Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP), Mylan (Valsartan-containing products), Teva Pharmaceuticals (Amlodipine/Valsartan Combination Tables and Amlopidine/Valsartan/Hydrochlorothiazide Combination Tablets), Mylan (Amlodipine and Valsartan Tablets; Valsartan Tablets; Valsartan and Hydrochlorothiazide Tablets), Torrent Pharmaceuticals Limited (Losartan potassium tablets, USP).

To learn more from the FDA, click here.